300015 Aier Eye Hospital Group
- 12.58
- -0.03-0.24%
Aier Eye Hospital Group News
Aier Ophthalmology (300015.SZ): There was no change in the trend of increasing market share in the cataract business in the first quarter
Gelonghui, May 16 | Aier Ophthalmology (300015.SZ) recently said during a survey reception from institutional investors that in 2023, the company's cataract business showed relatively rapid growth and increased market share. The main reasons include: 1. Release of the backlog of demand due to the epidemic; 2. The company's medical technology and service quality have been further improved, and its influence continues to expand, and reputation and patient satisfaction continue to improve; 3. The company provides different surgical options and adapts to various crystal categories to meet the diverse needs of patients, help patients solve basic problems, and meet the needs of personalized and customized surgical services. The first of these is the short-term factor, and
Aier Ophthalmology (300015): Performance is in line with expectations, optimistic about the company's long-term development
Matters: On April 25, 2024, the company released its 23 annual report and 24 quarterly report. The company's revenue in '23 was $20.367 billion (+26.43%), and net profit to mother was $3.359 billion (+3)
Strong inflow of foreign capital is another trend vane: Middle Eastern tycoons increase their presence in China, and multinational sovereign wealth funds continue to lay out A-shares
① The Abu Dhabi Investment Authority and the Kuwait Investment Authority held a large number of A-share listed companies in the first quarter; ② the Middle East Sovereign Fund also stepped up research on A-shares ③ Other overseas sovereign wealth funds are increasing their layout in the Chinese market.
Aier Ophthalmology (300015): Net profit to mother increased 15% year-on-year in the first quarter of 2024, leading ophthalmology companies showed business resilience
Maintaining high-quality development in a changing environment, net profit to mother increased 33% year-on-year in 2023. Achieved revenue of $20.367 billion (+26.43%) and net profit of $3.359 billion (+33.07) in 2023
Aier Ophthalmology (300015): Steady revenue growth, impressive profit growth rate in 24Q1
Incident Recently, the company released the 2023 Annual Report and the 2024 First Quarter Report. In 2023, the company achieved revenue of 20.367 billion yuan (+26.43%) and realized net profit of 3.359 billion yuan (+33) to mother
Core assets were generally adjusted. Lixun Precision fell more than 3%, while Dongfang Yuhong, Jinshan Office, Aier Ophthalmology, and Mindray Healthcare all fell by more than 2%.
Core assets were generally adjusted. Lixun Precision fell more than 3%, while Dongfang Yuhong, Jinshan Office, Aier Ophthalmology, and Mindray Healthcare all fell by more than 2%.
Aier Ophthalmology (300015): Steady performance growth, “1+8+N” strategy continues to advance
Key points: Revenue in 2023 increased 26.43% year on year, and net profit to mother increased by 33.07% year on year Event: Recently, the company released its 2023 annual report and 2024 quarterly report. The company went into business in 2023
Aier Ophthalmology (300015) Aier Ophthalmology 2023 Report & 2024 Quarterly Report Review: Resuming high growth in 23, optimistic about steady future growth
Investment Highlights: Announcement: Aier Ophthalmology Releases 2023 Annual Report and 2024 First Quarter Report? Comment: Results in 2023 resumed high growth, and profit margins continued to rise in the first quarter of 2024. In 2023,
Aier Ophthalmology (300015.SZ) has repurchased a total of 113.104 million shares at a cost of 204 million yuan
Aier Ophthalmology (300015.SZ) announced that the company purchased 1131.0 of the company's shares through centralized bidding transactions...
Aier Ophthalmology (300015) 2023 Report & 2024 Quarterly Report Review: Performance is in line with expectations, leading ophthalmology leaders demonstrate business resilience
Introduction to this report: In the short term, due to high base figures, consumption environment, etc., revenue growth has slowed, and performance is in line with expectations. The company insists on implementing the 1+8+N development strategy domestically, steadily advancing the international layout, and further consolidating and strengthening its comprehensive advantages. Maintain and increase your holdings
Aier Ophthalmology (300015): Performance is in line with expectations, leading ophthalmology leaders demonstrate business resilience
Introduction to this report: In the short term, due to high base figures, consumption environment, etc., revenue growth has slowed, and performance is in line with expectations. The company insists on implementing the 1+8+N development strategy domestically, steadily advancing the international layout, and further consolidating and strengthening its comprehensive advantages. Maintain and increase your holdings
Aier Ophthalmology (300015): Consumer pressure focuses on changes in business logic and anticipates layout expansion
Incident: On April 25, 2024, Aier Ophthalmology released the 2023 Report and 24Q1 Report. The company achieved revenue of 20.367 billion yuan (+26.43%) in 2023 and net profit of 3.359 billion yuan (+
Aier Ophthalmology (300015): 2024Q1 results meet expectations and achieve steady growth
Investment highlights: Event: The company announced its 2023 annual report and 2024 quarterly report. Achieved revenue of $20.367 billion (+26.43%) and net profit to mother of $3.359 billion (+33.07%) in 2023
Express News | Sinqi Eye Medicine: Aier Eye Hospital Group and others have reached a cooperation with the company and will introduce low-concentration atropine in the near future
Aier Ophthalmology (300015): 23 years of steady growth, 24Q1 under short-term pressure
Core view: Aier Ophthalmology reports 2023 and 2024Q1 results. In 2023, the company achieved operating income of 20.367 billion yuan, +26.43% year-on-year; net profit to mother was 3.359 billion yuan, year-on-year +
Aier Ophthalmology (300015) 2023 Report and 2024 Quarterly Report Review: Ophthalmology Leader Balancing Steady Growth, Shareholder Returns, and Social Responsibility
Incident: Aier Ophthalmology released its 2023 annual report and 2024 quarterly report on April 25: In 2023, the company achieved revenue of 20.4 billion yuan (+26%, year-on-year scale, same below) and net profit of 33.59 billion yuan to mother
Aier Ophthalmology (300015): 2024Q1 performance was slightly lower than expected and continued repurchases boosted market confidence
Incident Overview Recently, the company released the 2023 Annual Report & 2024 Quarterly Report, with 2023 revenue of 20.367 billion yuan (+26.4%) and net profit of 3.359 billion yuan (+33.1%) to mother, net profit of 3.359 billion yuan (+33.1%), deducted from Africa
Aier Ophthalmology (300015): 1Q profit growth was steady, optimistic about the upward trend throughout the year
Under the influence of internal and external factors, the profit side continued to grow steadily in 1Q24, maintaining that “buy” rated companies achieved revenue/net profit of 203.7/3.36 billion yuan in 23 years (yoy +26.4%/+33.1%), 1Q2
Aier Ophthalmology (300015): Growth decelerated due to high base and macro environment, Q1 refraction continued to grow
Incident: The company announced that in 2023, it achieved revenue of 20.367 billion yuan (+26.43%), net profit to mother of 3.359 billion yuan (+33.07%), and net profit of non-return to mother of 3,514 billion yuan (+20.
Aier Ophthalmology (300015): Performance is in line with expectations, and business resilience is highlighted
Performance summary: The company released its 2024 quarterly report and 2023 annual report. The first quarter of 2024 achieved revenue of 5.2 billion yuan (+3.5%) and net profit to mother of 900 million yuan (+15.2%), or approximately 8.4 billion yuan after deduction
Analysis
Price Target
No Data
